Rallybio Corporation

RLYB

$16.86

-0.09%

2026-09-04 12:20:43 EDT-$0.02

Salud

Biotecnología

NASDAQ

Negociación activa

Rallybio Corporation es una empresa de biotecnología en fase clínica dedicada a descubrir y llevar al mercado terapias transformadoras para las personas ...

Métricas clave de RLYB

Instantánea

Último / TTM · 6 periodos

Capitalización

$88.93M

ROCE

-25.1%

EV / EBITDA

-0.15x

+23.2% YoY

Rendimiento FCF

29.6%

+126.1% YoY

Ciclo de conversión de efectivo

-39.0d

Ratio corriente

27.26

Resumen rápido

TTM —

Sin señales de riesgo importantes en las métricas seleccionadas.

Métricas clave

Último / TTM · 6 periodos

Tendencia de valoración

Tendencia de valoración table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$306.52M	$209.07M	$96.67M	$41.80M	$30.91M	$88.93M
Enterprise ValueCompany value including debt and cash adjustments.	$131.19M	$152.66M	$72.57M	$28.05M	$-292,758.7	$-3.92M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	0.00x	44.11x	-0.34x	-6.06x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-2.89x	-2.25x	-0.92x	-0.46x	0.01x	-0.15x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	3.86	0.83	0.31	0.23	1.12	-3.44

Retornos + indicador ROCE

ROCE más reciente

-25.1%

Prev year -48.4%

Retornos + indicador ROCE table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-26.8%	-39.4%	-70.2%	-93.7%	-15.5%	68.6%
ROAProfit generated from total assets.	-25.8%	-36.9%	-64.5%	-84.8%	-14.4%	46.5%
ROICReturn generated on invested operating capital.	-26.0%	-40.0%	-74.4%	-97.8%	-49.0%	27.9%
ROCEOperating return on long-term capital used.	-26.0%	-40.0%	-74.2%	-97.8%	-48.4%	-25.1%
Earnings YieldEarnings as a percentage of market value.	-15.3%	-31.9%	-77.1%	-138.2%	-29.1%	47.7%

Calidad del flujo de caja

Calidad del flujo de caja table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-45.86M	$-57.34M	$-60.28M	$-49.28M	$-29.81M	$26.34M
FCFECash flow available to equity holders after debt flows.	$-45.87M	$-57.34M	$-60.28M	$-49.28M	$-29.81M	$26.34M
FCF YieldFree cash flow divided by market capitalization.	-15.0%	-27.4%	-62.4%	-117.9%	-96.5%	29.6%
Income QualityHow well accounting earnings are backed by cash flow.	0.97	0.86	0.81	0.85	3.32	0.58
Capex / OCFShare of operating cash flow spent on capital expenditures.	-0.7%	-0.1%	-0.0%	0.0%	0.0%	0.0%

Eficiencia operativa

Eficiencia operativa table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	2019.2d	0.0d	2374.9d	2.6d	499.9d	39.0d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	-2019.2d	0.0d	-2374.9d	-2.6d	-499.9d	-39.0d

Instantánea

Último / TTM: —

Capitalización

$88.93M

ROE

68.6%

Rendimiento FCF

29.6%

Ratio corriente

27.26

Cadena de suministro de RLYB

Upstream / Downstream / Proxy

Upstream

Affibody ABSwedish Orphan Biovitrum AB (Sobi)STO:SOBIAbCellera Biologics Inc.NASDAQ:ABCL Recursion Pharmaceuticals (via Exscientia legacy)NASDAQ:RXRX Johnson & Johnson Innovation — JJDCNYSE:JNJUnnamed CDMO Partner(s)Unnamed CRO Partner(s)

Downstream

Johnson & Johnson (via Momenta Pharmaceuticals subsidiary)NYSE:JNJAvenzo TherapeuticsUnconfirmedRecursion PharmaceuticalsNASDAQ:RXRX

Empresas proxy

Apellis Pharmaceuticals Inc.NASDAQ:APLS Alexion Pharmaceuticals (AstraZeneca Rare Disease)NASDAQ:AZN Recursion Pharmaceuticals Inc.NASDAQ:RXRXCandid Therapeutics Inc.Unconfirmed

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal